Vnitr Lek 2008, 54(6):623-631

Treatment of haemorrhage with transfusion preparations and blood derivatives

A. Buliková*, M. Matýšková, M. Penka
Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc.

Appropriate use of blood components and blood products improved both patients care and use of health care resources. In bleeding and/or risk bleeding situations use of these products is often indicated. The authors summarise different guidelines, experiences, indications and problems in hemotherapy concerning bleeding complications.

Keywords: bleeding; blood components; blood products; indications

Received: February 4, 2008; Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Buliková A, Matýšková M, Penka M. Treatment of haemorrhage with transfusion preparations and blood derivatives. Vnitr Lek. 2008;54(6):623-631.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Schmidt PJ. Hemotherapy: from bloodletting magic to transfusion medicine. Transfusion 2006; 46: 166-168. Go to original source... Go to PubMed...
    2. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43: 668-676. Go to original source... Go to PubMed...
    3. Heddle NM, Cook RJ, Webert KE et al. Methodologic issues in use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003; 43: 742-752. Go to original source... Go to PubMed...
    4. Stanworth SJ, Brunskill SJ, Hyde CJ et al. Is fresh frozen plasma clinically effective? A systematic review of radomized controlled trials. Br J Hematol 2004; 126; 139-152. Go to original source... Go to PubMed...
    5. Siegennthaler MA, Schneider PH, Tissott JD. Haemovigilance in a general university hospital: need for a more comprehensive classification and a codification of transfusion-related events. Vox Sanguinis 2005; 88: 22-30. Go to original source... Go to PubMed...
    6. Turek P. Properties of blood components and plasma fractions. In: Heier HE, Turek P, Walterová L (eds). ETSM Residential Course. Clinical transfusion medicine. Liberec 29. 3-3. 4. 2006: 19-30.
    7. Spence RK. Clinical use of plasma and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 83-96. Go to original source... Go to PubMed...
    8. Murphy MF, Wallington TB. Blood Transfusion Task Force. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001; 113: 24-31. Go to original source... Go to PubMed...
    9. Stainsby D, MacLennan S, Thomas D et al. British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135: 634-641. Go to original source... Go to PubMed...
    10. van Klei WA, Moons KGM, Leyssius AT et al. A reduction in type and screen: Preoperative prediction of RBC transfusions in surgery procedures with intermediate transfusions risks. Br J Anaesthesia 2001; 87: 250-257. Go to original source... Go to PubMed...
    11. O'Shaughnessy DF, Atterbury C, Maggs PB et al. British Committee for Standards in Hematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28. Go to original source... Go to PubMed...
    12. Spence RK. Clinical use of plasma and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 83-96. Go to original source... Go to PubMed...
    13. Walterová L. The role of platelets, FFP and coagulation factors. In: Heier HE, Turek P, Walterová L (eds). ETSM Residential Course. Clinical transfusion medicine. Liberec 29. 3.-2. 4. 2006.
    14. Barnett SL, Cimo M, Matevosyan K et al. Study of coagulation factors in patients with mild prolongation of prothrombin time. Implication for neurosurgical patients. Neurosurgery 2004; 55; 487. Go to original source...
    15. Holland LL, Foster TM, Marlar RA et al. Fresh frozen plasma is ineffective for correcting minimally elevated international normalized ratio. Transfusion 2005; 45: 1234-1235. Go to original source... Go to PubMed...
    16. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006; 46: 1279-1285. Go to original source... Go to PubMed...
    17. Stanworth SJ, Brunskill SJ, Murphy MF et al. Appraisal of the evidence for the clinical use of FFP and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 67-82. Go to original source... Go to PubMed...
    18. Dzik W, Rao A. Why do physicians request fresh frozen plasma? Transfusion 2004; 44: 1393-1394. Go to original source... Go to PubMed...
    19. Palo R, Capraro L, Hovilehto S et al. Population-based audit of fresh-frozen plasma transfusion practices. Transfusion 2006; 46: 1921-1925. Go to original source... Go to PubMed...
    20. Levi M, de Jonge E, van der Poll T. Plasma and plasma components in the management of disseminated intravascular coagulation. Best Pract Res Clin Haematol 2006; 19: 127-142. Go to original source... Go to PubMed...
    21. Erber WN, Perry DJ. Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol 2006; 19: 97-112. Go to original source... Go to PubMed...
    22. Hardy JF, de Moerloose P, Samama CM. The coagulopathy of massive transfusion. Vox Sanguinis 2005; 89: 123-127. Go to original source... Go to PubMed...
    23. Weippert-Kretschmet M, Karger R, Kretscher V. Peri-operative/post-traumatic haemostatic disorders: therapy. In: Heier HE, Turek P, Walterová L (eds). ETSM Residential Course. Clinical transfusion medicine. Liberec 29. 3.-2. 4. 2006: 145-152.
    24. Isaacs MS, Scheuermaier KD, Levy BL at al. In vitro efects of thawing fresh-frozen plasma at various temperatures. Clin Appl Thromb/Hemost 2004; 10: 143-148. Go to original source...
    25. Gumulec J, Kesseler P, Penka M et al. Krvácivé komplikace při léčbě warfarinem. Vnitř Lék 2006; 52: 79-95.
    26. Penka M, Buliková A, Gumulec J et al. Příprava nemocných na dlouhodobé antikoagulační léčbě kumariny k invazivním zákrokům. Vnitř Lék 2006; 52(Suppl 1): 35-40. Go to PubMed...
    27. Bulik O. Extrakce zubů a antikoagulační terapie - srovnání různých postupů. Prakt Zubn Lek 2004; 52; 68-77.
    28. Ansell J, Hirsh J, Poller H et al. The pharmacology and management of the vitamin K antagonists. Chest 2004; 2004: 204S-233S. Go to original source... Go to PubMed...
    29. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. Br J Haematol 2005; 132: 277-285. Go to original source... Go to PubMed...
    30. Ramsey G. Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review. Best Pract Res Clin Haematol 2006; 19: 113-126. Go to original source... Go to PubMed...
    31. Deitcher SR. Interpretation of the INR in patients with liver disease. Lancet 2002; 359: 47-48. Go to original source... Go to PubMed...
    32. McCullough J. Current issues with platelet transfusion in patients with cancers. Semin Hematol 2000; 37(Suppl 4): 3-10. Go to original source... Go to PubMed...
    33. Arnold DM, Crowther MA, Cook RJ et al. Utilisation of platelet transfusion in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion 2006; 46: 1286-1291. Go to original source... Go to PubMed...
    34. Greeno E, McCullough G, Weinsdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion 2007; 47: 201-205. Go to original source... Go to PubMed...
    35. Cameron B, Rock G, Olberg B et al. Evaluation of platelet transfusion trigger in a tertiary-care hospital. Transfusion 2007; 47: 206-211. Go to original source... Go to PubMed...
    36. Corash L. How much do we know about the platelet transfusion threshold? Transfusion 2003; 43: 691-693. Go to original source... Go to PubMed...
    37. British committee of standards in haematology, blood transfusion task force: Guideline for the use of platelet transfusion. Br J Haematol 2003; 122: 10-23.
    38. Lasota Z, Gumulec J, Janek D et al. Substituční hemoterapie. Doporučení pro klinickou praxi v zařízeních EUROMEDNET [online]. Dostupné z <www.pr-lab.cz>.
    39. Brand A. Transfusion support in malignant diseases. In: Heier HE, Turek P, Walterová L (eds). ETSM Residential Course. Clinical transfusion medicine. Liberec 29. 3.-2. 4. 2006: 67-75.
    40. Feies D, Innerhofer P, Schobersberg W. Coagulation management in trauma patients. Curr Opin Anaestesiol 2002; 15: 217-223. Go to original source... Go to PubMed...
    41. Bátorová A, Horváthová D, de Moerloose P et al. Fenotypová a genotypová analýza vrodenej hypofibrinogenémia a dysfibrinogenémie. Vnitř Lék 2005; 51: 802-808.
    42. Fries D, Krismer A, Klinger A et al. Effect of fibrinogen on reversal of dilutional coagulaopahty: a porcine model. Br J Anaestesia 2005; 95: 172-178. Go to original source... Go to PubMed...
    43. Charbit B, Mandelbrot L, Samain E et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2006; 5: 266-273. Go to original source... Go to PubMed...
    44. Lorenz R, Kiencast J, Otto U et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastrenterol Hepatol 2003; 15: 15-20. Go to original source... Go to PubMed...
    45. Lankiewitz MW, Hays J, Friedman KD et al. Urgent reversal of warfarin prothrombin complex concentrate. J Thromb Haemost 2005; 4: 967-970. Go to original source... Go to PubMed...
    46. Dusel CHH, Grundmann C, Eich S et al. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 2004; 15: 405-411. Go to original source... Go to PubMed...
    47. Matýšková M. Poruchy krevního srážení. In: Penka M, Buliková A, Matýšková M et al. Hematologie. Praha: Grada Publishing 2001: Vol. 1, 131-166.
    48. Hedner U, Kiesel W. Use of human factor VIIa in the treatment of two hemofilie A patients with high-titer inhibitors. J Clin Invest 1998; 71: 1836-1841. Go to original source... Go to PubMed...
    49. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-3064. Go to original source... Go to PubMed...
    50. Mathew P, Simon TL, Hunt KE et al. How we manage request for recombinant factor VIIa (NovoSeven). Transfusion 2007; 47: 8-14. Go to original source... Go to PubMed...
    51. Levi M. Recombinant factor FVIIa: a general hemostatic agent? Not yet. J Thromb Haemost 2004; 2: 1695-1697. Go to original source... Go to PubMed...
    52. Roberts HR. Recombinant hemostatic agent? J Thromb Haemost 2004; 2: 1691-1694. Go to original source... Go to PubMed...
    53. Černý V, Cvachovec K, Kasal E et al. Zásady podpory koagulace u život ohrožujícího a neztišitelného krvácení. Anest Inten Med 2005; 6: 314-315.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.